EZH2 and breast cancer: For example, LINC00511 showed oncogenic function in ER-negative BC via interaction with EZH2 and recruiting PRC2 to mediate H3K27me3 modification in the promoter region of CDKN1B, which led to the suppression of CDKN1B expression.